Adaptimmune Annual report [Section 13 and 15(d), not S-K Item 405]

Accrued expenses and other current liabilities

12 Months Ended

Dec. 31, 2024

Note 9 — Accrued expenses and other current liabilities

Accrued expenses and other current liabilities consisted of the following (in thousands):


	December 31,		December 31,
	2024		2023
Accrued clinical and development expenditure	$	11,931	$	12,351
Accrued commercial expenses and provisions		218		—
Accrued employee expenses		13,529		13,226
VAT payable		—		1,398
Other accrued expenditure		5,221		3,277
Other		2,020		51
	$	32,919	$	30,303